Evidence map›Paper›PMID 34886058›Full record

Trial reportInternational journal of environmental research and public health2021

Does Direct-to-Consumer Personal Genetic Testing Improve Gynecological Cancer Screening Uptake among Never-Screened Attendees? A Randomized Controlled Study.

Miki Watanabe, Satoyo Hosono, Hiroko Nakagawa-Senda, Sachiyo Yamamoto, Masami Aoyama, Satoru Hattori, Tamaki Yamada, Sadao Suzuki

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Miki WatanabeDepartment of Public Health, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.ORCID 0000-0003-0222-9629
Satoyo HosonoDepartment of Public Health, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Hiroko Nakagawa-SendaDepartment of Public Health, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.
Sachiyo YamamotoHealth Promotion Division, Okazaki City Public Health Center, Okazaki 444-8545, Japan.
Masami AoyamaHealth Promotion Division, Okazaki City Public Health Center, Okazaki 444-8545, Japan.
Satoru HattoriOkazaki City Public Health Center, Okazaki 444-8545, Japan.
Tamaki YamadaOkazaki City Medical Association, Public Health Center, Okazaki 444-0875, Japan.
Sadao SuzukiDepartment of Public Health, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.ORCID 0000-0001-5988-4849
Nagoya City University · JPOkazaki City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical impact of direct-to-consumer genetic testing (DTC-GT) on health behavior change has remained controversial. The aim of this study is to clarify the short-term effects of DTC-GT on gynecological cancer screening uptake among middle-aged never-screened Japanese women in a randomized controlled trial (RCT). A total of 144 women aged 45-50 who had never undergone gynecological cancer screening were randomly selected to receive health education (control group), or health education and DTC-GT (intervention group), at a 1:1 ratio. We compared the gynecological screening uptake during the follow-up period. Furthermore, to estimate the impact of learning of an elevated genetic cancer risk in the intervention group, we conducted an analysis dichotomized by genetic risk category. A total of 139 women completed the one-year follow-up survey (69 in the control group and 70 in the intervention group). The follow-up period did not differ between control and intervention groups (the median follow-up period was 276 days and 279 days, respectively,

Indexed as

Direct-To-Consumer Screening and TestingUterine Cervical NeoplasmsEarly Detection of CancerFemaleGenetic TestingHumansMass ScreeningMiddle Agedbreast cancercancer screeningcervical cancergenetic testingrandomized controlled trialscreening uptake

Identifiers

PMID34886058
PMCPMC8657107
OpenAlexW3216288464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.